PIK3CD and hematopoietic and lymphoid system neoplasm: Pik3cd encodes a phosphoinositide 3-kinase that is involved in the immune response, has been previously associated with idiopathic sudden sensorineural hearing loss [63], and is targeted by the drug idelalisib, approved to treat certain blood cancers.